Diabetes and Frailty: An Expert Consensus Statement on the Management of Older Adults with Type 2 Diabetes.
Elderly
Frailty
Treatment choices
Type 2 diabetes
Journal
Diabetes therapy : research, treatment and education of diabetes and related disorders
ISSN: 1869-6953
Titre abrégé: Diabetes Ther
Pays: United States
ID NLM: 101539025
Informations de publication
Date de publication:
May 2021
May 2021
Historique:
received:
23
12
2020
accepted:
13
02
2021
pubmed:
9
4
2021
medline:
9
4
2021
entrez:
8
4
2021
Statut:
ppublish
Résumé
Prognosis and appropriate treatment goals for older adults with diabetes vary greatly according to frailty. It is now recognised that changes may be needed to diabetes management in some older people. Whilst there is clear guidance on the evaluation of frailty and subsequent target setting for people living with frailty, there remains a lack of formal guidance for healthcare professionals in how to achieve these targets. The management of older adults with type 2 diabetes is complicated by comorbidities, shortened life expectancy and exaggerated consequences of adverse effects from treatment. In particular, older adults are more prone to hypoglycaemia and are more vulnerable to its consequences, including falls, fractures, hospitalisation, cardiovascular events and all-cause mortality. Thus, assessment of frailty should be a routine component of a diabetes review for all older adults, and glycaemic targets and therapeutic choices should be modified accordingly. Evidence suggests that over-treatment of older adults with type 2 diabetes is common, with many having had their regimens intensified over preceding years when they were in better health, or during more recent acute hospital admissions when their blood glucose levels might have been atypically high, and nutritional intake may vary. In addition, assistance in taking medications, as often occurs in later life following implementation of community care strategies or admittance to a care home, may dramatically improve treatment adherence, leading to a fall in glycated haemoglobin (HbA1c) levels. As a person with diabetes gets older, simplification, switching or de-escalation of the therapeutic regimen may be necessary, depending on their level of frailty and HbA1c levels. Consideration should be given, in particular, to de-escalation of therapies that may induce hypoglycaemia, such as sulphonylureas and shorter-acting insulins. We discuss the use of available glucose-lowering therapies in older adults and recommend simple glycaemic management algorithms according to their level of frailty.
Identifiants
pubmed: 33830409
doi: 10.1007/s13300-021-01035-9
pii: 10.1007/s13300-021-01035-9
pmc: PMC8099963
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
1227-1247Références
Strain WD, Hope SV, Green A, Kar P, Valabhji J, Sinclair AJ. Type 2 diabetes mellitus in older people: a brief statement of key principles of modern day management including the assessment of frailty. A national collaborative stakeholder initiative. Diabet Med. 2018;35:838–45.
International Diabetes Federation. Global guideline for managing older people with type 2 diabetes. 2013. https://www.idf.org/e-library/guidelines/78-global-guideline-for-managing-older-people-with-type-2-diabetes.html . Accessed 14 Oct 2020.
LeRoith D, Biessels GJ, Braithwaite SS, et al. Treatment of diabetes in older adults: an Endocrine Society* clinical practice guideline. J Clin Endo Metab. 2019;104:1520–74.
Sinclair AJ, Abdelhafiz A, Dunning T, et al. An international position statement on the management of frailty in diabetes mellitus: summary of recommendations 2017. J Frailty Aging. 2018;7:10–20.
Hambling CE, Khunti K, Cos X, et al. Factors influencing safe glucose-lowering in older adults with type 2 diabetes: a PeRsOn-centred ApproaCh To IndiVidualisEd (PROACTIVE) Glycemic Goals for older people: a position statement of Primary Care Diabetes Europe. Prim Care Diabetes. 2019;13:330–52.
pubmed: 30792156
American Diabetes Association. 12. Older adults: standards of medical care in diabetes—2020. Diabetes Care. 2020;43:S152–S62.
Sinclair AJ, Heller SR, Pratley RE, et al. Evaluating glucose-lowering treatment in older people with diabetes: lessons from the IMPERIUM trial. Diabetes Obes Metab. 2020;22:1231–42.
pubmed: 32100382
pmcid: 7383926
Strain WD, Blüher M, Paldánius P. Clinical inertia in individualising care for diabetes: is there time to do more in type 2 diabetes? Diabetes Ther. 2014;5:347–54.
pubmed: 25113408
pmcid: 4269638
Clegg A, Young J, Iliffe S, Rikkert MO, Rockwood K. Frailty in elderly people. Lancet. 2013;381:752–62.
pubmed: 23395245
Clegg A, Bates C, Young J, et al. Development and validation of an electronic frailty index using routine primary care electronic health record data. Age Ageing. 2016;45:353–60.
pubmed: 26944937
pmcid: 26944937
Podsiadlo D, Richardson S. The timed “Up & Go”: a test of basic functional mobility for frail elderly persons. J Am Geriatr Soc. 1991;39:142–8.
Nordin E, Rosendahl E, Lundin-Olsson L. Timed, “Up & Go” test: reliability in older people dependent in activities of daily living—focus on cognitive state. Phys Ther. 2006;86:646–55.
pubmed: 16649889
Morley JE, Malmstrom TK, Miller DK. A simple frailty questionnaire (FRAIL) predicts outcomes in middle aged African Americans. J Nutr Health Aging. 2012;16:601–8.
pubmed: 22836700
pmcid: 22836700
Sinclair AJ, Abdelhafiz AH, Forbes A, Munshi M. Evidence-based diabetes care for older people with type 2 diabetes: a critical review. Diabet Med. 2019;36:399–413.
pubmed: 30411402
NHS England. 2019/20 General Medical Services (GMS) contract quality and outcomes framework (QOF). Guidance for GMS contract 2019/20 in England. 2019. https://www.england.nhs.uk/wp-content/uploads/2019/05/gms-contract-qof-guidance-april-2019.pdf . Accessed 14 Oct 2020.
Kiniwa N, Okumiya T, Tokuhiro S, Matsumura Y, Matsui H, Koga M. Hemolysis causes a decrease in HbA1c level but not in glycated albumin or 1,5-anhydroglucitol level. Scand J Clin Lab Investig. 2019;79:377–80.
English E, Idris I, Smith G, Dhatariya K, Kilpatrick ES, John WG. The effect of anaemia and abnormalities of erythrocyte indices on HbA1c analysis: a systematic review. Diabetologia. 2015;58:1409–21.
pubmed: 25994072
Guo W, Zhou Q, Jia Y, Xu J. Increased levels of glycated hemoglobin A1c and iron deficiency anemia: a review. Med Sci Monit. 2019;25:8371–8.
pubmed: 31696865
pmcid: 6857442
Ahmad J, Rafat D. HbA1c and iron deficiency: a review. Diabetes Metab Syndr. 2013;7:118–22.
pubmed: 23680254
Heller SR, DeVries JH, Wysham C, Hansen CT, Hansen MV, Frier BM. Lower rates of hypoglycaemia in older individuals with type 2 diabetes using insulin degludec versus insulin glargine U100: results from SWITCH 2. Diabetes Obes Metab. 2019;21:1634–41.
pubmed: 30891886
pmcid: 6618254
McCluskey L, Jagger O, Strain WD. Hypoglycemia associated with impaired mobility and diminished confidence in an elderly person with type 2 diabetes. Diabet Hypoglycemia. 2014;7:11–4.
Liu GX, Chen Y, Yang YX, et al. Pilot study of the Mini Nutritional Assessment on predicting outcomes in older adults with type 2 diabetes. Geriatr Gerontol Int. 2017;17:2485–92.
pubmed: 28657169
Sanz Paris A, Garcia JM, Gomez-Candela C, et al. Malnutrition prevalence in hospitalized elderly diabetic patients. Nutr Hosp. 2013;28:592–9.
pubmed: 23848076
American Diabetes Association. 12. Older adults: standards of medical care in diabetes—2021. Diabetes Care. 2021;44:S168–S79.
Franz MJ, Bantle JP, Beebe CA, et al. Nutrition principles and recommendations in diabetes. Diabetes Care. 2004;27(Suppl 1):S36-46.
pubmed: 14693924
Lew QJ, Jafar TH, Koh HW, et al. Red meat intake and risk of ESRD. J Am Soc Nephrol. 2017;28:304–12.
pubmed: 27416946
Kidney Disease: Improving Global Outcomes Diabetes Work Group. KDIGO 2020 clinical practice guideline for diabetes management in chronic kidney disease. Kidney Int. 2020;2020(98):S1–115.
Rodriguez-Mañas L, Laosa O, Vellas B, et al. Effectiveness of a multimodal intervention in functionally impaired older people with type 2 diabetes mellitus. J Cachexia Sarcopenia Muscle. 2019;10:721–33.
pubmed: 31016897
pmcid: 6711410
Park SW, Goodpaster BH, Strotmeyer ES, et al. Accelerated loss of skeletal muscle strength in older adults with type 2 diabetes: the health, aging, and body composition study. Diabetes Care. 2007;30:1507–12.
pubmed: 17363749
Kalyani RR, Corriere M, Ferrucci L. Age-related and disease-related muscle loss: the effect of diabetes, obesity, and other diseases. Lancet Diabetes Endocrinol. 2014;2:819–29.
pubmed: 24731660
pmcid: 4156923
Cauza E, Strehblow C, Metz-Schimmerl S, et al. Effects of progressive strength training on muscle mass in type 2 diabetes mellitus patients determined by computed tomography. Wien Med Wochenschr. 2009;159:141–7.
pubmed: 19343291
Seaquist ER, Anderson J, Childs B, et al. Hypoglycemia and diabetes: a report of a workgroup of the American Diabetes Association and the Endocrine Society. Diabetes Care. 2013;36:1384–95.
pubmed: 23589542
pmcid: 23589542
Hope SV, Taylor PJ, Shields BM, Hattersley AT, Hamilton W. Are we missing hypoglycaemia? Elderly patients with insulin-treated diabetes present to primary care frequently with non-specific symptoms associated with hypoglycaemia. Prim Care Diabetes. 2018;12:139–46.
pubmed: 28918198
pmcid: 5857285
Freeman J. Management of hypoglycemia in older adults with type 2 diabetes. Postgrad Med. 2019;131:241–50.
pubmed: 30724638
Brož J, Urbanová J, Frier BM. Hypoglycemia in the elderly: watch for atypical symptoms. J Fam Pract. 2019;68:74.
pubmed: 30870543
Sinclair A, Dunning T, Rodriguez-Mañas L. Diabetes in older people: new insights and remaining challenges. Lancet Diabetes Endocrinol. 2015;3:275–85.
Abdelhafiz AH, Rodriguez-Manas L, Morley JE, Sinclair AJ. Hypoglycemia in older people—a less well recognized risk factor for frailty. Aging Dis. 2015;6:156–67.
pubmed: 25821643
pmcid: 4365959
Pathak RD, Schroeder EB, Seaquist ER, et al. Severe hypoglycemia requiring medical intervention in a large cohort of adults with diabetes receiving care in U.S. integrated health care delivery systems: 2005–2011. Diabetes Care. 2016;39:363–70.
pubmed: 26681726
Yun JS, Ko SH, Ko SH, et al. Cardiovascular disease predicts severe hypoglycemia in patients with type 2 diabetes. Diabetes Metab J. 2015;39:498–506.
pubmed: 26370882
pmcid: 4696986
Sinclair AJ, Bellary S. Preventing hypoglycaemia: an elusive quest. Lancet Diabetes Endocrinol. 2016;4:635–6.
pubmed: 27293217
Bonds DE, Miller ME, Bergenstal RM, et al. The association between symptomatic, severe hypoglycaemia and mortality in type 2 diabetes: retrospective epidemiological analysis of the ACCORD study. BMJ. 2010;340:b4909.
pubmed: 20061358
pmcid: 2803744
Gerstein HC, Miller ME, Byington RP, et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008;358:2545–59.
pubmed: 18539917
Aurobindo Pharma-Milpharm Ltd. Metformin 500 mg (PL 16363/0111) tablets SmPC. 2020. https://www.medicines.org.uk/emc/medicine/23244#gref . Accessed 09 Dec 2020.
Maruthur NM, Tseng E, Hutfless S, et al. Diabetes medications as monotherapy or metformin-based combination therapy for type 2 diabetes: a systematic review and meta-analysis. Ann Intern Med. 2016;164:740–51.
pubmed: 27088241
Sola D, Rossi L, Schianca GP, et al. Sulfonylureas and their use in clinical practice. Arch Med Sci. 2015;11:840–8.
pubmed: 26322096
pmcid: 4548036
Rosenstock J, Kahn SE, Johansen OE, et al. Effect of linagliptin vs glimepiride on major adverse cardiovascular outcomes in patients with type 2 diabetes: the CAROLINA randomized clinical trial. JAMA. 2019;322:1155–66.
pubmed: 31536101
pmcid: 6763993
de Jong M, van der Worp HB, van der Graaf Y, Visseren FLJ, Westerink J. Pioglitazone and the secondary prevention of cardiovascular disease. A meta-analysis of randomized-controlled trials. Cardiovasc Diabetol. 2017;16:134.
pubmed: 29037211
pmcid: 5644073
Lewis JD, Habel LA, Quesenberry CP, et al. Pioglitazone use and risk of bladder cancer and other common cancers in persons with diabetes. JAMA. 2015;314:265–77.
pubmed: 26197187
Zhu ZN, Jiang YF, Ding T. Risk of fracture with thiazolidinediones: an updated meta-analysis of randomized clinical trials. Bone. 2014;68:115–23.
pubmed: 25173606
Billington EO, Grey A, Bolland MJ. The effect of thiazolidinediones on bone mineral density and bone turnover: systematic review and meta-analysis. Diabetologia. 2015;58:2238–46.
pubmed: 26109213
Schwartz AV, Chen H, Ambrosius WT, et al. Effects of TZD use and discontinuation on fracture rates in ACCORD bone study. J Clin Endocrinol Metab. 2015;100:4059–66.
pubmed: 26305617
pmcid: 4702444
Buse JB, Wexler DJ, Tsapas A, et al. 2019 Update to: management of hyperglycemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2018;2020(43):487–93.
Strain WD, Lukashevich V, Kothny W, Hoellinger MJ, Paldánius PM. Individualised treatment targets for elderly patients with type 2 diabetes using vildagliptin add-on or lone therapy (INTERVAL): a 24 week, randomised, double-blind, placebo-controlled study. Lancet. 2013;382:409–16.
pubmed: 23706759
Sinha B, Ghosal S. Meta-analyses of the effects of DPP-4 inhibitors, SGLT2 inhibitors and GLP1 receptor analogues on cardiovascular death, myocardial infarction, stroke and hospitalization for heart failure. Diabetes Res Clin Pract. 2019;150:8–16.
pubmed: 30794833
Milne N. How to use GLP-1 receptor agonist therapy safely and effectively. Diabetes Prim Care. 2020;22:135–6.
Novo Nordisk Limited. Rybelsus SmPC. 2020. https://www.medicines.org.uk/emc/product/11507/smpc#gref . Accessed 14 Oct 2020.
Strain WD, Griffiths J. A systematic review and meta-analysis of the impact of GLP-1 receptor agonists and SGLT-2 inhibitors on cardiovascular outcomes in biologically healthy older adults. Br J Diabetes. 2021. https://doi.org/10.15277/bjd.2021.292 .
Strain WD, Holst AG, Rasmussen S, Saevereid HA, James MA. Effects of liraglutide and semaglutide on stroke subtypes in patients with type 2 diabetes: a post hoc analysis of the LEADER, SUSTAIN 6 and PIONEER 6 trials (ePoster 398). European Society of Cardiology Congress (ESC 365), 29 Aug to 2 Sept 2020, Amsterdam.
Scheen AJ. Effects of glucose-lowering agents on surrogate endpoints and hard clinical renal outcomes in patients with type 2 diabetes. Diabetes Metab. 2019;45:110–21.
pubmed: 30477733
Brown P. How to use SGLT2 inhibitors safely and effectively. Diabetes Prim Care. 2021;23(1):5–7.
Davidson JA. SGLT2 inhibitors in patients with type 2 diabetes and renal disease: overview of current evidence. Postgrad Med. 2019;131:251–60.
pubmed: 30929540
Hsia DS, Grove O, Cefalu WT. An update on sodium-glucose co-transporter-2 inhibitors for the treatment of diabetes mellitus. Curr Opin Endocrinol Diabetes Obes. 2017;24:73–9.
pubmed: 27898586
pmcid: 6028052
Pettus J, Santos Cavaiola T, Tamborlane WV, Edelman S. The past, present, and future of basal insulins. Diabetes Metab Res Rev. 2016;32:478–96.
pubmed: 26509843
Novo Nordisk A/S. Tresiba (insulin degludec) summary of product characteristics. 2020. https://www.ema.europa.eu/en/medicines/human/EPAR/tresiba#product-information-section . Accessed 17 Dec 2020.
Sanofi-Aventis Deutschland GmBH. Toujeo summary of product characteristics. 2020. https://www.ema.europa.eu/en/medicines/human/EPAR/toujeo-previously-optisulin#product-information-section . Accessed 17 Dec 2020.
American Diabetes Association. 9. Pharmacologic approaches to glycemic treatment: standards of medical care in diabetes—2019. Diabetes Care. 2019;42:S90–S102.
McCoy RG, Lipska KJ, Van Houten HK, Shah ND. Paradox of glycemic management: multimorbidity, glycemic control, and high-risk medication use among adults with diabetes. BMJ Open Diabetes Res Care. 2020;8(1):e001007.
Weiner JZ, Gopalan A, Mishra P, et al. Use and discontinuation of insulin treatment among adults aged 75 to 79 years with type 2 diabetes. JAMA Intern Med. 2019;179:1633–41.
pubmed: 31545376
pmcid: 6763990
Abdelhafiz AH, Sinclair AJ. Deintensification of hypoglycaemic medications-use of a systematic review approach to highlight safety concerns in older people with type 2 diabetes. J Diabetes Complicat. 2018;32:444–50.
Tan LF, Ho Wen Teng V, Seetharaman SK, Yip AW. Facilitating telehealth for older adults during the COVID-19 pandemic and beyond: strategies from a Singapore geriatric center. Geriatr Gerontol Int. 2020;20:993–5.
pubmed: 33003250
pmcid: 7537120
Abrashkin KA, Poku A, Ball T, Brown ZJ, Rhodes KV. Ready or not: pivoting to video visits with homebound older adults during the COVID-19 pandemic. J Am Geriatr Soc. 2020;68:2469–71.
pubmed: 33020899
pmcid: 7675583
Isakovic M, Sedlar U, Volk M, Bester J. Usability pitfalls of diabetes mHealth apps for the elderly. J Diabetes Res. 2016;2016:1604609.
pubmed: 27034957
pmcid: 4807066
Mappangara I, Qanitha A, Uiterwaal C, Henriques JPS, de Mol B. Tele-ECG consulting and outcomes on primary care patients in a low-to-middle income population: the first experience from Makassar telemedicine program. Indones BMC Fam Pract. 2020;21:247.
Bergenstal RM, Layne JE, Zisser H, et al. Remote application and use of real-time continuous glucose monitoring by adults with type 2 diabetes in a virtual diabetes clinic. Diabetes Technol Ther. 2021;23(2):128–32.
Sy SL, Munshi MN. Caring for older adults with diabetes during the COVID-19 pandemic. JAMA Intern Med. 2020;180:1147–8.
pubmed: 32658279
Valentine V, Goldman J, Shubrook JH. Rationale for, initiation and titration of the basal insulin/GLP-1RA fixed-ratio combination products, IDegLira and IGlarLixi, for the management of type 2 diabetes. Diabetes Ther. 2017;8:739–52.
pubmed: 28721686
pmcid: 5544623
Min SH, Yoon JH, Hahn S, Cho YM. Comparison between SGLT2 inhibitors and DPP4 inhibitors added to insulin therapy in type 2 diabetes: a systematic review with indirect comparison meta-analysis. Diabetes Metab Res Rev. 2017;33(1):e2818.
Hope SV, Jones AG, Goodchild E, et al. Urinary C-peptide creatinine ratio detects absolute insulin deficiency in type 2 diabetes. Diabet Med. 2013;30:1342–8.
pubmed: 23659458
pmcid: 4154136
Pernicova I, Korbonits M. Metformin—mode of action and clinical implications for diabetes and cancer. Nat Rev Endocrinol. 2014;10:143–56.
pubmed: 24393785
[No authors listed]. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet. 1998;352:854–65.
Aroda VR, Edelstein SL, Goldberg RB, et al. Long-term metformin use and vitamin B12 deficiency in the Diabetes Prevention Program Outcomes Study. J Clin Endocrinol Metab. 2016;101:1754–61.
pubmed: 26900641
pmcid: 4880159
Seino S, Sugawara K, Yokoi N, Takahashi H. β-Cell signalling and insulin secretagogues: a path for improved diabetes therapy. Diabetes Obes Metab. 2017;19(Suppl 1):22–9.
pubmed: 28880474
Toh S, Hampp C, Reichman ME, et al. Risk for hospitalized heart failure among new users of saxagliptin, sitagliptin, and other antihyperglycemic drugs: a retrospective cohort study. Ann Intern Med. 2016;164:705–14.
pubmed: 27110660
pmcid: 5178978
Simes BC, MacGregor GG. Sodium-glucose cotransporter-2 (SGLT2) inhibitors: a clinician’s guide. Diabetes Metab Syndr Obes. 2019;12:2125–36.
pubmed: 31686884
pmcid: 6799898
Davidson MA, Mattison DR, Azoulay L, Krewski D. Thiazolidinedione drugs in the treatment of type 2 diabetes mellitus: past, present and future. Crit Rev Toxicol. 2018;48:52–108.
pubmed: 28816105